ARS Pharmaceuticals, Inc. SPRY 深 滬
已收盤 07-02 16:00:00 美东时间
8.56
+0.620
+7.81%
華盛通- 最 高8.61
- 今 開8.14
- 成交量 179.64万股
- 最 低 8.00
- 昨 收 7.94
- 總市值 8.50亿
- 52周最高 18.63
- 市盈率 靜 --
- 換手率 1.81%
- 52周最低 6.66
- 委 比 1.35%
- 總股本 9930.33万
- 歷史最高 63.41
- 量 比 0.53
- 振 幅 7.68%
- 歷史最低 2.55
- 每 手 1
- 風險率 2.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 2% on Thursday. Shares of H.B. Fuller Company (NYSE:FUL) fell sharply in pre-market trading following second-quarter results. H.B. Fuller posted upbeat earnings for the second quarter and raised its FY2026 ear...
06-25 20:08
ARS Pharmaceuticals Continues To Reduce Cash-Based Operating Expenses After No New Commercial Formulary Additions Or Coverage Decisions Have Been Issued For Neffy In The Latest Cycle
Access and payer coverage: Despite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy in the July 1, 2026 cycle. ARS Pharma intends to continue working with the remaining payers, and notes...
06-25 04:13
ARS Pharmaceuticals Provides Commercial and Financial Updates
ARS Pharmaceuticals updated on its neffy® (epinephrine nasal spray) payer access and financial outlook. No new commercial formulary additions or coverage decisions were issued for neffy in the July 1, 2026 cycle, though discussions continue. The company lowered its 2026 cash-based operating expenses to $248 million and reaffirmed its path to cash-flow breakeven in 2027. The Phase 2b CSU trial interim data is expected in Q4 2026, with neffy demand...
06-24 20:05
ARS Pharma Chief Commercial Officer Eric Karas sells 25,000 shares for $250,000
ARS Pharma Chief Commercial Officer Eric Karas sells 25,000 shares for $250,000 ARS Pharmaceuticals Chief Commercial Officer Eric Karas exercised options for 25,000 common shares at USD 1.5 on June 12, 2026. Karas sold 25,000 common shares at USD 10 on June 12, 2026. Directly held common shares fell
06-13 08:06
ARS Pharma Chief Legal Officer Alexander Fitzpatrick sells 3,355 shares for $33,550
ARS Pharma Chief Legal Officer Alexander Fitzpatrick sells 3,355 shares for $33,550 ARS Pharmaceuticals Chief Legal Officer Alexander A. Fitzpatrick sold 3,355 common shares on June 12, 2026 at USD 10. Fitzpatrick’s post-transaction stake totaled 90,910 common shares, held directly. Disclaimer: This
06-13 08:05
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30
Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.
05-28 22:06
电话会总结 ｜ ARS Pharma(SPRY)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据ARS Pharmaceuticals业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收：8,430万美元，包括： - 美国净产品营收：7,220万美元（首个完整商业化年度） - 合作协议营收：970万美元 - 供应营收：240万美元 **成本与费用：** - 销售及管理费用（SG&A）：2.301亿美元，主要用于商业化投资，包括销售团队和直接面向消费者（DTC）营销活动 - 研发费用（R&D）：1,320万美元，主要用于产品开发和临床试验执行 **毛利率指标：** - 毛净比率（Gross t
05-16 12:03
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter financial results on F...
05-15 21:31
